Use of fast-acting insulin aspart in insulin pump therapy in clinical practice

被引:36
|
作者
Evans, Mark [1 ,2 ]
Ceriello, Antonio [3 ,4 ,5 ,6 ]
Danne, Thomas [7 ]
De Block, Christophe [8 ]
DeVries, J. Hans [9 ,10 ]
Lind, Marcus [11 ,12 ]
Mathieu, Chantal [13 ]
Norgaard, Kirsten [14 ]
Renard, Eric [15 ,16 ]
Wilmot, Emma G. [17 ]
机构
[1] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, Box 289 Addenbrookes Hosp,Hills Rd, Cambridge CB2 0QQ, England
[2] Univ Cambridge, Dept Med, Box 289 Addenbrookes Hosp,Hills Rd, Cambridge CB2 0QQ, England
[3] IRCCS MultiMed, Milan, Italy
[4] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[5] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
[6] IRCCS MultiMed, Dept Cardiovasc & Metab Dis, Sesto San Giovanni, Italy
[7] Kinderkrankenhaus Bult, Diabet Zentrum Kinder & Jugendliche, Hannover, Germany
[8] Antwerp Univ Hosp, Dept Endocrinol Diabetol Metab, Edegem, Belgium
[9] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands
[10] Profil Inst Metab Res, Neuss, Germany
[11] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden
[12] NU Hosp Grp, Dept Med, Trollhattan Uddevalla, Sweden
[13] Univ Hosp Leuven, Clin & Expt Endocrinol, Leuven, Belgium
[14] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[15] Univ Montpellier, Montpellier Univ Hosp, Dept Endocrinol, Diabet,Nutr,CNRS,INSERM, Montpellier, France
[16] Univ Montpellier, Inst Funct Genom, CNRS, INSERM, Montpellier, France
[17] Univ Hosp Derby & Burton NHS Fdn Trust, Derby, England
来源
DIABETES OBESITY & METABOLISM | 2019年 / 21卷 / 09期
关键词
CSII; insulin pump therapy; GLUCOSE CONTROL; HIGH-FAT; TYPE-1; BOLUS; CHILDREN; EXCURSIONS; INFUSION; DELIVERY; ADULTS; ADOLESCENTS;
D O I
10.1111/dom.13798
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the additional excipients niacinamide and L-arginine. The improved pharmacological profile and greater early glucose-lowering action of faster aspart compared with IAsp suggests that faster aspart may be advantageous for people with diabetes using continuous subcutaneous insulin infusion (CSII). The recent onset 5 trial was the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants with type 1 diabetes (T1D). Non-inferiority of faster aspart to IAsp in terms of change from baseline in HbA1c was confirmed, with an estimated treatment difference (ETD) of 0.09% (95% CI, 0.01; 0.17; P < 0.001 for non-inferiority [0.4% margin]). Faster aspart was superior to IAsp in terms of change from baseline in 1-hour post-prandial glucose (PPG) increment after a meal test (ETD [95% CI], -0.91 mmol/L [-1.43; -0.39]; P = 0.001), with statistically significant improvements also at 30 minutes and 2 hours. The overall rate of severe or blood glucose-confirmed hypoglycaemia was not statistically significantly different between treatments, with an estimated rate ratio of 1.00 (95% CI, 0.85; 1.16). A numerical imbalance in severe hypoglycaemic episodes between faster aspart and IAsp was seen in the treatment (21 vs 7) and the 4-week run-in periods (4 vs 0). Experience from clinical practice indicates that all pump settings should be reviewed when initiating faster aspart with CSII, and that the use of continuous glucose monitoring or flash glucose monitoring, along with a good understanding of meal content and bolus type, may also facilitate optimal use. This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and individuals with T1D successfully initiate and adjust faster aspart with CSII.
引用
收藏
页码:2039 / 2047
页数:9
相关论文
共 50 条
  • [31] Improved glycaemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes
    Twigg, Stephen
    Philis-Tsimikas, Athena
    Bode, Bruce
    Franek, Edward
    Rose, Ludger
    Buchholtz, Kristine
    Demissie, Marek
    Pieber, Thomas R.
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 89 : 64 - 64
  • [32] Improved glycaemic control with carbohydrate counting for adjustment of fast-acting insulin aspart vs insulin aspart in subjects with Type 1 diabetes
    Leelarathna, L.
    Philis-Tsimikas, A.
    Bode, B. W.
    Franek, E.
    Rose, L.
    Buchholtz, K.
    Pieber, T. R.
    [J]. DIABETIC MEDICINE, 2018, 35 : 19 - 19
  • [33] Improved glycaemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes
    Philis-Tsimikas, A.
    Bode, B. W.
    Franek, E.
    Rose, L.
    Buchholtz, K.
    Demissie, M.
    Pieber, T. R.
    [J]. DIABETOLOGIA, 2017, 60 : S315 - S315
  • [34] Efficacy and Safety of Fast-Acting Insulin Aspart in Adults with T2D with Different Insulin Requirements
    Lane, Wendy
    Ekelund, Magnus
    Thorisdottir, Olof
    Jodar, Esteban
    Oviedo, Alejandra
    Rathor, Naveen
    Senior, Peter
    Sesti, Giorgio
    Franek, Edward
    [J]. DIABETES, 2020, 69
  • [35] Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
    Hoevelmann, Ulrike
    Heise, Tim
    Nosek, Leszek
    Sassenfeld, Bettina
    Thomsen, Karen Margrete Due
    Haahr, Hanne
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (05) : 503 - 509
  • [36] Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
    Ulrike Hövelmann
    Tim Heise
    Leszek Nosek
    Bettina Sassenfeld
    Karen Margrete Due Thomsen
    Hanne Haahr
    [J]. Clinical Drug Investigation, 2017, 37 : 503 - 509
  • [37] AFREZZA: FAST-ACTING INHALED INSULIN
    Aschenbrenner, Diane S.
    [J]. AMERICAN JOURNAL OF NURSING, 2014, 114 (10) : 22 - 23
  • [38] Fast-acting insulin in snail venom
    Alexandra Le Bras
    [J]. Lab Animal, 2019, 48 : 113 - 113
  • [39] The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
    Leelarathna, Lalantha
    Ashley, Donna
    Fidler, Carrie
    Parekh, Witesh
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (07) : 187 - 197
  • [40] Fast-acting insulin in snail venom
    Le Bras, Alexandra
    [J]. LAB ANIMAL, 2019, 48 (04) : 113 - 113